Amphastar Pharmaceuticals, Inc. $AMPH Stock Holdings Increased by Systematic Financial Management LP

Systematic Financial Management LP boosted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 10.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 359,307 shares of the company’s stock after purchasing an additional 32,761 shares during the period. Systematic Financial Management LP owned approximately 0.77% of Amphastar Pharmaceuticals worth $8,250,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Amphastar Pharmaceuticals by 192.8% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company’s stock valued at $29,000 after purchasing an additional 831 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Amphastar Pharmaceuticals during the first quarter valued at about $39,000. Hantz Financial Services Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 3,430.8% in the second quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock worth $32,000 after buying an additional 1,338 shares during the period. IFP Advisors Inc increased its position in shares of Amphastar Pharmaceuticals by 75.7% in the second quarter. IFP Advisors Inc now owns 2,035 shares of the company’s stock worth $52,000 after acquiring an additional 877 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in shares of Amphastar Pharmaceuticals by 950.0% during the first quarter. Russell Investments Group Ltd. now owns 2,058 shares of the company’s stock valued at $60,000 after acquiring an additional 1,862 shares during the period. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

AMPH stock opened at $27.58 on Thursday. The firm has a 50 day moving average of $25.62 and a two-hundred day moving average of $25.59. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $45.39. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of 12.20, a P/E/G ratio of 7.69 and a beta of 0.91. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.10. The business had revenue of $191.84 million during the quarter, compared to analyst estimates of $186.90 million. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%. As a group, equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current fiscal year.

Analysts Set New Price Targets

AMPH has been the topic of several research analyst reports. Zacks Research cut shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Needham & Company LLC dropped their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, August 8th. Weiss Ratings restated a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a report on Monday. Finally, Bank of America upped their price target on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $31.20.

Insider Transactions at Amphastar Pharmaceuticals

In related news, Director Floyd F. Petersen sold 16,679 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $26.49, for a total value of $441,826.71. Following the completion of the sale, the director directly owned 75,531 shares in the company, valued at approximately $2,000,816.19. The trade was a 18.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Richard K. Prins sold 4,179 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $27.10, for a total value of $113,250.90. Following the sale, the director directly owned 35,183 shares of the company’s stock, valued at $953,459.30. The trade was a 10.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 21,858 shares of company stock valued at $581,313 in the last ninety days. Insiders own 27.50% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.